JANUARY, 2004

Diagnosis, Diagnostics, Immunodiagnosis & Immunodiagnostics:  

8549.  Baker B, Evans M, DeCastro F, Schosser R. Leprosy in a Mexican immigrant. J Ky Med Assoc. 2003 Jul;101(7):289-94.

8550.  Delobel P, Launois P, Djossou F, Sainte-Marie D, Pradinaud R. American cutaneous leishmaniasis, lepromatous leprosy, and pulmonary tuberculosis coinfection with downregulation of the T-helper 1 cell response. Clin Infect Dis. 2003 Sep 1;37(5):628-33. Epub 2003 Aug 07.

8551.  Jardim MR, Antunes SL, Santos AR, Nascimento OJ, Nery JA, Sales AM, Illarramendi X, Duppre N, Chimelli L, Sampaio EP, Sarno EP. Criteria for diagnosis of pure neural leprosy. J Neurol. 2003 Jul;250(7):806-9.

8552.  Kang TJ, Kim SK, Lee SB, Chae GT, Kim JP. Comparison of two different PCR amplification products (the 18-kDa protein gene vs. RLEP repetitive sequence) in the diagnosis of Mycobacterium leprae. Clin Exp Dermatol. 2003 Jul;28(4):420-4.

Pathogenesis:

8553.  Bleharski JR, Li H, Meinken C, Graeber TG, Ochoa MT, Yamamura M, Burdick A, Sarno EN, Wagner M, Rollinghoff M, Rea TH, Colonna M, Stenger S, Bloom BR, Eisenberg D, Modlin RL.  Use of genetic profiling in leprosy to discriminate clinical forms of the disease. Science. 2003 Sep 12;301(5639):1527-30.

8554.  Cemerski S, van Meerwijk JP, Romagnoli P. Oxidative-stress-induced T lymphocyte hyporesponsiveness is caused by structural modification rather than proteasomal degradation of crucial TCR signaling molecules. Eur J Immunol. 2003 Aug;33(8):2178-85.

8555.  Salem II, Steffan G, Duzgunes N. Efficacy of clofazimine-modified cyclodextrin against Mycobacterium avium complex in human macrophages. Int J Pharm. 2003 Jul 9;260(1):105-14.

Therapy:

8556.  Greenstein RJ. Is Crohn's disease caused by a mycobacterium? Comparisons with leprosy, tuberculosis, and Johne's disease. Lancet Infect Dis. 2003 Aug;3(8):507-14. Review.

8557.  Perri AJ 3rd, Hsu S. A review of thalidomide's history and current dermatological applications. Dermatol Online J. 2003 Aug;9(3):5. Review.

8558.  Sayal SK; Das AL; Deora MS Trial of ofloxacin in paucibacillary leprosy Indian Journal of Dermatology. 2003 Jan-Mar; 48(1): 27-9.

APRIL, 2004

 Diagnosis, Diagnostics, Immunodiagnosis & Immunodiagnostics:  

9214.  Erhabor GE, Adewole O, Adisa AO, Olajolo OA. Directly observed short course therapy for tuberculosis--a preliminary report of a three-year experience in a teaching hospital. J Natl Med Assoc. 2003 Nov;95(11):1082-8.

9215.  Lee HN, Embi CS, Vigeland KM, White CR Jr. Concomitant pulmonary tuberculosis and leprosy. J Am Acad Dermatol. 2003 Oct;49(4):755-7.

Therapy:

9216.  Ustianowski AP, Lockwood DN. Leprosy: current diagnostic and treatment approaches. Curr Opin Infect Dis. 2003 Oct;16(5):421-7. Review.

JULY, 2004

 Diagnosis, Diagnostics, Immunodiagnosis & Immunodiagnostics:  

9913.   Dugue C, Perraut R, Youinou P, Renaudineau Y. Effects of anti-endothelial cell antibodies in leprosy and malaria. Infect Immun. 2004 Jan;72(1):301-9.

9914.   Ebenezer GJ, Daniel E. Expression of protein gene product 9.5 in lepromatous eyes showing ciliary body nerve damage and a "dying back" phenomenon in the posterior ciliary nerves. Br J Ophthalmol. 2004 Feb;88(2):178-81.

9915.   Geluk A, van Meijgaarden KE, Franken KL, Wieles B, Arend SM, Faber WR, Naafs B, Ottenhoff TH. Immunological crossreactivity of the Mycobacterium leprae CFP-10 with its homologue in Mycobacterium tuberculosis. Scand J Immunol. 2004 Jan;59(1):66-70.

9916.   Imaz MS, Comini MA, Zerbini E, Sequeira MD, Latini O, Claus JD, Singh M. Evaluation of commercial enzyme-linked immunosorbent assay kits for detection of tuberculosis in Argentinean population. J Clin Microbiol. 2004 Feb;42(2):884-7

9917.   Ravindran R, Anam K, Bairagi BC, Saha B, Pramanik N, Guha SK, Goswami RP, Banerjee D, Ali N. Characterization of immunoglobulin G and its subclass response to Indian kala-azar infection before and after chemotherapy. Infect Immun. 2004 Feb;72(2):863-70.

9918.   Sinha S, Mahadevan A, Lokesh L, Ashraf V, Chandrasekhar Sagar BK, Taly AB, Shankar SK. Tangier disease--a diagnostic challenge in countries endemic for leprosy. J Neurol Neurosurg Psychiatry. 2004 Feb;75(2):301-4.

    Pathogenesis:

9919. de la Barrera S, Finiasz M, Fink S, Ilarregui J, Aleman M, Olivares L, Franco MC, Pizzariello G, del Carmen Sasiain M. NK cells modulate the cytotoxic activity generated by Mycobacterium leprae-hsp65 in leprosy patients: role of IL-18 and IL-13. Clin Exp Immunol. 2004 Jan;135(1):105-13.

9920. Hunger RE, Sieling PA, Ochoa MT, Sugaya M, Burdick AE, Rea TH, Brennan PJ, Belisle JT, Blauvelt A, Porcelli SA, Modlin RL. Langerhans cells utilize CD1a and langerin to efficiently present nonpeptide antigens to T cells. J Clin Invest. 2004 Mar;113(5):701-8.

9921. Matsuoka M, Zhang L, Budiawan T, Saeki K, Izumi S. Genotyping of Mycobacterium leprae on the basis of the polymorphism of TTC repeats for analysis of leprosy transmission. J Clin Microbiol. 2004 Feb;42(2):741-5.

9922. Prevot G, Bourreau E, Pascalis H, Pradinaud R, Tanghe A, Huygen K, Launois P.  Differential production of systemic and intralesional gamma interferon and interleukin-10 in nodular and ulcerative forms of Buruli disease. Infect Immun. 2004 Feb;72(2):958-65.

Vaccines:

9923.   Al-Attiyah R, Mustafa AS.  Computer-assisted prediction of HLA-DR binding and experimental analysis for human promiscuous Th1-cell peptides in the 24 kDa secreted lipoprotein (LppX) of Mycobacterium tuberculosis. Scand J Immunol. 2004 Jan;59(1):16-24.

    Therapy:

9924. Crawford CL. Licensing thalidomide in Australia. Med J Aust. 2004 Feb 16;180(4):199-200; discussion 200.

9925. Laffitte E, Revuz J. Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf. 2004 Jan;3(1):47-56. Review.

9926. Staples J. Delineating disease: self-management of leprosy identities in South India. Med Anthropol. 2004 Jan-Mar;23(1):69-88.

9927. Villahermosa LG, Fajardo TT Jr, Abalos RM, Cellona RV, Balagon MV, Dela Cruz EC, Tan EV, Walsh GP, Walsh DS. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy. Am J Trop Med Hyg. 2004 Feb;70(2):197-200.

OCTOBER, 2004

Diagnosis, Diagnostics, Immunodiagnosis & Immunodiagnostics:  

 10548.Spencer JS, Kim HJ, Marques AM, Gonzalez-Juarerro M, Lima MC, Vissa VD, Truman RW, Gennaro ML, Cho SN, Cole ST, Brennan PJ. Comparative analysis of B- and T-cell epitopes of Mycobacterium leprae and Mycobacterium tuberculosis culture filtrate protein 10. Infect Immun. 2004 Jun;72(6):3161-70.

10549.  Britton WJ, Lockwood DN. Leprosy. Lancet. 2004 Apr 10;363(9416):1209-19. Review.

Pathogenesis:

10550.Nepal BP, Shrestha UD. Ocular findings in leprosy patients in Nepal in the era of multidrug therapy. Am J Ophthalmol. 2004 May;137(5):888-92.

10551.Sunderkotter CH, Tomimori-Yamashita J, Nix V, Maeda SM, Sindrilaru A, Mariano M, Sorg C, Roth J. High expression of myeloid-related proteins 8 and 14 characterizes an inflammatorily active but ineffective response of macrophages during leprosy. Immunology. 2004 Apr;111(4):472-80.

Therapy:

10552.  Crawford CL.  Does thalidomide have a role in leprosy? Lancet. 2004 Jun 5;363(9424):1911.